NPM1 and acute myeloid leukemia: In this retrospective EBMT registry‐based study, we evaluated the predictive factors of posttransplant outcomes and the individual and aggregate impact of FLT3‐ITD mutation, disease status, and MRD at transplant at transplant in 1572 adult (age ≥18 years) patients known to have NPM1‐mutated normal karyotype AML.